Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.52 |
| ▸ | FNTA | P49354 | 3/20 | 0.50 |
| ▸ | FNTB | P49356 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.46 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200064 | 1.00 | NOD1 (0.52) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL21587882 | 1.00 | NOD1 (0.52) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL17204611 | 0.87 | NOD1 (0.70) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL4741209 | 0.87 | NOD1 (0.70) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL5664925 | 0.87 | NOD1 (0.70) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL25188855 | 0.87 | NOD1 (0.70) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL4741211 | 0.87 | NOD1 (0.70) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL25264982 | 0.87 | NOD1 (0.70) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL11426235 | 0.87 | NOD1 (0.70) | NOD1FNTAFNTBMEN1KMT2A | |
| SCHEMBL542916 | 0.87 | NOD1 (0.70) | NOD1FNTAFNTBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304999-B1 | ANTIPERSPIRANT FORMULATIONS | UNILEVER PLC (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20070116662-A1 | Antiperspirant/deodorant compositions | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-05-24 | — | — | US | disclosed |
| WO-2007058735-A1 | ANTIPERSPIRANT/DEODORANT COMPOSITIONS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1304999-A1 | ANTIPERSPIRANT FORMULATIONS | UNILEVER PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| US-20020039563-A1 | Antiperspirant formulations | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC | 2002-04-04 | — | — | US | disclosed |
| US-6361766-B1 | ANHYDROUS FORMULATION COMPRISING PARTICULATE ANTIPERSPIRANT SUSPENDED IN WATER-IMMISCIBLE CARRIER FLUID COMPRISING OXYGEN-CONTAINING EMOLLIENT OIL HAVING SPECIFIED REFRACTIVE INDEX STRUCTURED BY WAX OR NONPOLYMERIC FIBER-FORMING GELLANT | UNILEVER HOME & PERSONAL CARE, USA DIVISION OF CONOPCO, INC. | 2002-03-26 | — | — | US | disclosed |
| US-20020034481-A1 | Antiperspirant formulations | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002011691-A1 | ANTIPERSPIRANT FORMULATIONS | UNILEVER PLC (GB) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002011692-A1 | ANTIPERSPIRANT FORMULATIONS | UNILEVER PLC (GB) | 2002-02-14 | — | — | WO | disclosed |
| US-3969087-A | Gels of nonpolar liquids with N-acyl amino acids and derivatives thereof as gelling agents | AJINOMOTO CO., LTD. (JA) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020034481-A1 | Antiperspirant formulations | ADH1A, SOAT1, CUTA | NOD1 3590/4885FNTA 1164/4885FNTB 1107/4885 |
| US-20070116662-A1 | Antiperspirant/deodorant compositions | PUF60, DDT, DECR1 | NOD1 4844/4885FNTA 1494/4885FNTB 1100/4885 |
| US-20020039563-A1 | Antiperspirant formulations | ADH1A, SOAT1, CUTA | NOD1 4094/4885FNTA 1206/4885FNTB 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.